Form 4: RTW Investments Acquires Pre-Funded Warrants in Rocket Pharmaceuticals

RTW Investments, LP acquired pre-funded warrants for 400,000 shares of Rocket Pharmaceuticals common stock in a private placement.

Summary

• RTW Investments, LP, along with related parties, acquired pre-funded warrants for 400,000 shares of Rocket Pharmaceuticals common stock on December 12, 2024.
• The warrants were purchased at a price of $0.01 each and are exercisable at any time after December 12, 2024.
• The exercise of the warrants is subject to a blocker that prevents the holder from owning more than 9.99% of the outstanding common stock after exercise.
• As of the transaction, RTW Investments beneficially owns 3,526,955 shares of Rocket Pharmaceuticals common stock indirectly.
• The filing also notes that RTW Investments may be deemed a director by deputization due to the board positions held by its partners.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, but the continued investment by RTW Investments is a positive sign for Rocket Pharmaceuticals. The 9.99% blocker is a standard provision and does not significantly impact the sentiment.

Positives

• The acquisition of pre-funded warrants indicates a continued investment by RTW Investments in Rocket Pharmaceuticals.
• The warrants provide RTW Investments with the potential to increase its stake in the company in the future.

Negatives

• The exercise of the warrants is limited by a 9.99% ownership blocker, which may restrict RTW Investments' ability to fully capitalize on the warrants.

Risks

• The 9.99% ownership blocker could limit the potential upside for RTW Investments from the warrants.
• The value of the warrants is dependent on the future performance of Rocket Pharmaceuticals' stock.

Future Outlook

The pre-funded warrants provide RTW Investments with the option to increase its stake in Rocket Pharmaceuticals, subject to the ownership blocker.

Management Comments

• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest.
• This report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

This transaction is a common occurrence in the biotech industry, where investment firms often use warrants to gain exposure to potential upside while managing risk.

Comparison to Industry Standards

• Private placements of warrants are a typical method for biotech companies to raise capital.
• The 9.99% ownership blocker is a common provision to prevent investors from triggering change of control provisions.
• RTW Investments' investment is similar to other institutional investors who take positions in biotech companies with promising pipelines.

Related Party Transactions

• The pre-funded warrant was purchased from the Issuer in a private placement.

Stakeholder Impact

• Shareholders may view the continued investment by RTW Investments as a positive sign.
• The transaction does not appear to have a significant impact on other stakeholders.

Next Steps

• RTW Investments may exercise the warrants in the future, subject to the ownership blocker.
• Rocket Pharmaceuticals will likely continue to monitor its ownership structure.

Key Dates

Keywords

RTW Investments, Rocket Pharmaceuticals, Pre-Funded Warrants, Beneficial Ownership, Private Placement, Director Deputization, Securities Exchange Act